In two previous clinical studies, TAS-117 has shown clinical efficacy in PIK3CA mutated endometrial and ovarian cancers, and in patients with ovarian clear cell carcinoma and had a manageable safety profile across patients with all cancer types enrolled in these studies [21,22]. This evidence concerns the gene PIK3CA and ovarian clear cell cancer.